ALAllan Lipton

Allan Lipton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Allan Lipton has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Alison T. Stopeck

    Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York, New York

    3 shared publications
  • Karim Fizazi

    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France

    3 shared publications
  • Ada Braun

    Amgen Inc

    2 shared publications
  • David H. Henry

    Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA

    2 shared publications
  • Fred Saad

    Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec, Canada

    2 shared publications
  • Janet E. Brown

    Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield, United Kingdom

    2 shared publications

Latest Publications

  • Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

    by Diep Ho, Jessica Huang, Judith-Anne W. Chapman, Kim Leitzel, Suhail M. Ali, Lois Shepherd, Wendy R. Parulekar, Catherine E. Ellis, Rocco J. Crescnzo, Liting Zhu, et al.

    Background The lapatinib–taxane combination led to shorter PFS than trastuzumab–taxane in HER2+ metastatic breast cancer. We investigated the prognostic and predictive effects of pretreatment serum HER2, CAIX, and TIMP-1. Methods MA.31 accrued 652 patients; 537 (82%) were centrally confirmed HER2+. Biomarkers were categorized for univariate and multivariable predictive investigations with a median cut-point, ULN cut-points (15 ng/ml for HER2; 506 pg/ml for CAIX; 454 pg/ml for TIMP-1), and custom cut-points (30 and 100 ng/ml for HER2). Stratified step-wise forward Cox multivariable analysis examined continuous and categorical effects of biomarkers on PFS in the ITT and central HER2+ populations; central HER2+ biomarker results are shown. Results Serum was banked for 472 (72%) of 652 patients. Higher serum HER2 (>median; >15; >30; or >100 ng/ml; p = 0.05–0.002); higher CAIX (>median; >506 pg/ml; p = 0.02; p = 0.001); and higher TIMP-1 (> median; > 454 pg/ml; p = 0.001; p = 0.02) had shorter univariate PFS. In multivariable analysis, higher continuous TIMP-1 was associated with significantly shorter PFS: HR = 1.001 (95% CI = 1.00–01.002; p = 0.004). Continuous serum HER2 and CAIX were not significantly associated with PFS. HER2 of 15 ng/ml or higher had shorter PFS (p = 0.02); higher categorical CAIX had shorter PFS (p = 0.01–0.08). Interaction terms of HER2, CAIX, and TIMP-1 with treatment were not significant; the predictive test power was low. Conclusions Higher levels of serum TIMP-1, CAIX, and HER2 were significant prognostic biomarkers of shorter PFS. We found no significant interaction between serum biomarkers and response to lapatinib versus trastuzumab. Evaluation of TIMP-1 and CAIX-targeted therapy in addition to HER2-targeted therapy appears warranted in patients with elevated serum levels of these biomarkers.


  • Open Access

    Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

    by Allan Lipton, Judith‐Anne W. Chapman, Kim Leitzel, Ashwani Garg, Kathleen I. Pritchard, James N. Ingle, G. Thomas Budd, Matthew J. Ellis, George W. Sledge, Manuela Rabaglio, et al.

    BACKGROUND: Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of osteoporosis. This study examined the effects of self‐reported osteoporosis and osteoporosis therapy (OPT) on outcomes.METHODS: The MA.27 phase 3 adjuvant trial enrolled 7576 postmenopausal women. The primary outcome was event‐free survival (EFS), and the secondary outcome was distant disease–free survival (DDFS). Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis. In a multivariate, stratified Cox regression, factors were significant with a 2‐sided Wald test P value ≤ .05.RESULTS: Osteoporosis was reported at the baseline by 654 of the 7576 women (8.6%) and in total by 1294 patients. Oral OPT was received at the baseline by 815 of the 7576 women (10.8%) and in total by 2711 patients (36%). With a median follow‐up of 4.1 years, 693 EFS events (9.15%) and 321 DDFS events (4.2%) occurred. Osteoporosis was not associated with EFS or DDFS. Few EFS events occurred before the initiation of OPT, with no substantive evidence of a time‐differing effect on outcomes (nonproportional hazards). OPT (yes vs no) was significantly associated with improved EFS (hazard ratio [HR] for yes vs no, 0.67; 95% confidence interval [CI], 0.57‐0.80; P < .001) and DDFS (HR, 0.57; 95% CI, 0.44‐0.73; P <. 001). Time‐differing (time‐dependent) OPT was not (EFS; P = .45). OPT did not alter the incidence of visceral‐only metastasis (P = .31).CONCLUSIONS: Oral OPT, administered to postmenopausal breast cancer patients receiving adjuvant AI therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time‐dependent effect) did not affect the outcome. OPT did not alter the risk of visceral metastasis. Cancer 2017;123:2444–51. © 2017 American Cancer Society.


  • Open Access

    Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

    by Allan Lipton, Matthew R. Smith, Karim Fizazi, Alison T. Stopeck, David Henry, Janet E. Brown, Neal D. Shore, Fred Saad, Andrew Spencer, Li Zhu, et al.

    Purpose: Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment. Experimental Design: This is an integrated analysis of patient-level data from three identically designed, blinded, phase III trials with patients randomized to subcutaneous denosumab or intravenous zoledronic acid. Levels of the BTMs urinary N-telopeptide (uNTx) and serum bone-specific alkaline phosphatase (sBSAP) measured at study entry and month 3 were analyzed. OS, DP, and DPB were compared in patients with BTMs ≥ median versus < median based on month 3 assessments. Results: uNTx levels ≥ the median of 10.0 nmol/mmol at month 3 were associated with significantly reduced OS compared with levels < median (HR for death, 1.85; P < 0.0001). sBSAP levels ≥ median of 12.6 ng/mL were associated with significantly reduced OS compared with levels < median (HR, 2.44; P < 0.0001). uNTx and sBSAP levels ≥ median at month 3 were associated with significantly greater risk of DP (HR, 1.31; P < 0.0001 and HR, 1.71; P < 0.0001, respectively) and DPB (HR, 1.11; P = 0.0407 and HR, 1.27; P < 0.0001, respectively). Conclusions: BTM levels ≥ median after 3 months of bone antiresorptive treatment were associated with reduced OS and increased risk of DP and DPB. Assessment of uNTx and sBSAP levels after bone antiresorptive therapy may add to identification of patients at risk for worse clinical outcomes. Clin Cancer Res; 22(23); 5713–21. ©2016 AACR.


  • Open Access

    Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

    by A. Lipton, K. Fizazi, A.T. Stopeck, D.H. Henry, M.R. Smith, N. Shore, M. Martin, S. Vadhan-Raj, J.E. Brown, G.E. Richardson, et al.


  • Open Access

    Hypocalcaemia in patients with metastatic bone disease treated with denosumab

    by Jean-Jacques Body, Henry G. Bone, Richard H. de Boer, Alison Stopeck, Catherine Van Poznak, Ronaldo Damião, Karim Fizazi, David H. Henry, Toni Ibrahim, Allan Lipton, et al.


  • Open Access

    Would Screening for Lung Cancer Benefit 75- to 84-Year-Old Residents of the United States?

    by John M. Varlotto, Malcolm M. DeCamp, John C. Flickinger, Jessica Lake, Abram Recht, Chandra P. Belani, Michael F. Reed, Jennifer W. Toth, Heath B. Mackley, Christopher N. Sciamanna, et al.

    Background: The National Lung Screening Trial demonstrated that screening for lung cancer improved overall survival (OS) and reduced lung cancer mortality in the 55-74-year-old age group by increasing the proportion of cancers detected at an early stage. Because of the increasing life expectancy of the American population, we investigated whether screening for lung cancer might benefit men and women aged 75-84 years. Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000-2009 were calculated in both these younger and older age groups using the Surveillance Epidemiology and End Reporting (SEER) database. OS and lung cancer -specific survival (LCSS) in patients with Stage I NSCLC diagnosed from 2004-2009 were analyzed to determine the effects of age and treatment. Results: The per capita incidence of NSCLC decreased in the 55-74 cohort, but increased in the 75-84 cohort over the study period. Crude lung cancer death rates in the two age groups who had no specific treatment were 39.5% and 44.9%, respectively. These rates fell in both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS improved significantly with increasingly aggressive treatment in the 75-84 age group. The survival benefits of increasingly aggressive treatment in 75-84 year old females did not differ from their counterparts in the younger cohort. Conclusions: Screening for lung cancer might be of benefit to individuals at increased risk of lung cancer in the age 75-84 group. The survival benefits of aggressive therapy are similar in females between 55-74 and 75-84 years old.


  • Elevation in Multiple Serum Inflammatory Biomarkers Predicts Survival of Pancreatic Cancer Patients with Inoperable Disease

    by A. Alkhateeb, L. Zubritsky, B. Kinsman, K. Leitzel, C. Campbell-Baird, S. M. Ali, J. Connor, A. Lipton


  • New Targeted Therapies for Bone Metastases

    by Allan Lipton, Luis Costa, Paul Sieber, William C. Dougall, Ada Braun

  • Open Access

    HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

    by Allan Lipton, Laurie Goodman, Kim Leitzel, Jennifer Cook, Jeff Sperinde, Mojgan Haddad, Wolfgang J. Köstler, Weidong Huang, Jodi M. Weidler, Suhail Ali, et al.

    Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trastuzumab insensitivity. We sought to investigate the potential of HER3 alone and in the context of p95HER2 (p95), a trastuzumab resistance marker, as biomarkers of trastuzumab escape. Using the VeraTag® assay platform, we developed a dual antibody proximity-based assay for the precise quantitation of HER3 total protein (H3T) from formalin-fixed paraffin-embedded (FFPE) breast tumors. We then measured H3T in 89 patients with metastatic breast cancer treated with trastuzumab-based therapy, and correlated the results with progression-free survival and overall survival using Kaplan–Meier and decision tree analyses that also included HER2 total (H2T) and p95 expression levels. Within the sub-population of patients that over-expressed HER2, high levels of HER3 and/or p95 protein expression were significantly associated with poor clinical outcomes on trastuzumab-based therapy. Based on quantitative H3T, p95, and H2T measurements, multiple subtypes of HER2-positive breast cancer were identified that differ in their outcome following trastuzumab therapy. These data suggest that HER3 and p95 are informative biomarkers of clinical outcomes on trastuzumab therapy, and that multiple subtypes of HER2-positive breast cancer may be defined by quantitative measurements of H3T, p95, and H2T.


  • Reply to Araki et al.

    by Allan Lipton, Karim Fizazi, Alison T. Stopeck, David H. Henry, Ada H. Braun